Group items tagged

Medical sector has the third highest number of businesses currently for sale, with hospitality and retail technology firms most likely to sell up next year, according to the UK Business Investment Report. There are 4,300 registered medical businesses in the UK, and approximately 355 (one in every 12.11) are currently up for sale. Topping the list was the hospitality sector with one in every 9.88 businesses up for sale, ahead of retail technology businesses (1 in 10.13). At the bottom of the table were owners of agriculture businesses with just one in every 943 businesses up for sale. Transportation and software/IT business owners followed in a similar manner with one in every 802 businesses being up for sale.

Boots registered a twelfth consecutive quarter of retail market share growth, with a reported retail sales increase of 5.9 per cent for the three months ending on 29 February 2024. This impressive growth comes on top of a 16 per cent increase recorded during the same period in the previous year, the UK's leading health and beauty retailer revealed. Strong growth was observed across digital platforms, namely Boots.com and the Boots app, with a 16.8 per cent surge in digital sales, particularly driven by "strong sales of beauty and personal care products." The growth of in-store sales remained consistent, registering a 4.5 per cent increase, with flagship, shopping center, and travel stores demonstrating particularly strong performance.

Whitworth Chemists Limited has instructed the property adviser, Christie & Co, to sell six of its pharmacies in Blackpool, as part of the company's wider portfolio sale across the North of England. The pharmacies are located on Kingscote Drive, Charles Street, Whitegate Drive, Bloomfield Road, Waterloo Road, and Common Edge Road. According to the specialist broker, these are high-dispensing pharmacies, dispensing an average of circa 9,700 items per month. Some of the accompanying freehold buildings are also up for sale, and interest is invited on a group, subgroup, or individual basis. Jon Booth, Director - Pharmacy at Christie & Co, who is handling the sale, said: "We are delighted to have been engaged by the family and shareholders of Whitworth Chemists Limited in this exciting project.

British pharmaceutical giant GlaxoSmithKline beat first-quarter sales and earnings forecasts on Wednesday (April 27), helped by demand for its Covid-19 therapy and shingles vaccine, as the company moves towards the July separation of its consumer health business. Profit after tax jumped 68 percent to £1.8 billion ($2.3 billion, 2.1 billion euros) compared with the start of 2021. Sales climbed 32 percent to almost £9.8 billion. "We have delivered strong first-quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth," chief executive Emma Walmsley said in the earnings statement. "Our results reflect further good momentum across speciality medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress." The shingles vaccine generated £698 million in quarterly sales, beating analyst estimates of 528 million. Walmsley is seeking to reshape GSK after facing fierce investor criticism over the company's delay in producing Covid jabs and treatments.

Sun Pharmaceutical Industries, India's largest drugmaker by revenue, reported a better-than-expected 5.2 per cent rise in third-quarter profit on Tuesday, driven by higher sales of its specialty drugs. The company, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, said it earned a consolidated net profit of 21.66 billion rupees ($265.23 million) in three months ended Dec. 31, up from 20.59 billion rupees last year. Analysts, on average, had expected the company to report a profit of 21.26 billion rupees, according to Refinitiv IBES data. Total revenue from operations climbed nearly 14 per cent to 112.41 billion rupees. Input costs rose 8.5 per cent. Drug sales in India rose 7.1 per cent to 33.92 billion rupees, whereas sales in the United States climbed 16.6 per cent to 34.66 billion rupees, with each of the two regions accounting for 31 per cent of the company's total consolidated sales. The company, founded in 1983, makes over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients for chronic and acute treatments.

Restricting sales of vape products to pharmacies is not a solution to curb illegal sales of vape among underage adults, said UK Vaping Industry Association (UKVIA). In an oral evidence at the House of Commons on 'Youth Vaping' called by the Health and Social Care Select Committee (HSSC) to figure out action needed to reduce vaping among those under 18. Rachael Maskell, York Central MP's suggested on vape products being available from licensed pharmacies. Marcus Saxton, Chairman, Independent British Vape Trade Association (IBVTA) said: "We are calling for further regulation to tighten up what has now been an extreme growth in single-use products. If you put them into those environments, as New Zealand and Australia are telling us, the perception of the public is that, while they can buy tobacco freely anywhere, the vaping product that is up to 95% safer is licensed through a pharmacy. It makes absolutely no sense. The negative consequence of considering such a thing will take us backwards years."

Walgreens Boots Alliance on Tuesday (June 28) scrapped the plan to sell its UK high street pharmacy chain saying no third party was able to make an adequate offer due to the turmoil in global financial markets. Walgreens' move to call off the sale comes as private equity bidders Apollo Global and TDR faced headwinds in raising financing for the deal, as banks were wary of underwriting large chunks of the financing due to tough market conditions. Boots was initially valued at as much as £8bn with the auction process being led by Goldman Sachs. Global economic uncertainty and rising inflation have triggered a spike in interest rates as central banks have rushed to take action in the most widespread tightening of monetary policy for more than two decades, making deal financing costlier and harder to access. Walgreens had put its Boots UK business up for sale after announcing a strategic review in January as the second-largest US pharmacy chain renewed its focus on domestic healthcare. The company said the decision to retain Boots and No7 Beauty Company was also underpinned by their ongoing strong performance.

Usdaw, one of the major trade unions in the UK, has sought assurances for its members working in Boots, following reports that the parent company of the iconic health and beauty retailer and pharmacy chain is considering putting the business on sale next year. Walgreen Boots Alliance (WBA), the US health group that owns a stake in Boots UK since 2012, is reportedly lining up Goldman Sachs to explore the sale of business with potential valuation of £10 billion. Currently, the process is thought to be solely exploratory and may not necessarily convert into the sale of the 172-year-old firm. Usdaw national officer, Daniel Adams, said: "We note that the company declined to comment on speculation, but acknowledged that the group's strategic direction 'includes a more pointed focus on North America and on healthcare'.

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

Buy online CP Wheelchair, Pediatric Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair for handicapped and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Karma CP Wheelchair, Pediatric Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair at low price in india for handicapped and disability product like CP 2 Pediatric Wheelchair, CP Pediatric Wheelchair, along with that we offer huge discount and promo code when you purchase CP PEDIATRIC WHEELCHAIR from our online shopping store of CP Wheelchair : Pediatric Wheelchair : Cerebral Palsy Wheelchair : CP Child Wheelchair : CP Wheelchair India : CP Wheelchair Price : Pediatric Wheelchair Costs : Pediatric Wheelchair for Sale : Karma Pediatric Wheelchair : Buy Cerebral Palsy Wheelchair : Cerebral Palsy Wheelchair India : Cerebral Palsy Wheelchair Price Starts from 14500 INR CP Pediatric Wheelchair Price 14500 INR Ultra light weight aluminum alloy frame Epoxy powder coated frame Detachable arm rest provided Height adjustable and detachable head rest Hydraulic reclining high back for a comfortable posture Detachable back and seat pad Extra cushion upholstery provided to under arm, head. Hand brakes provided Safety belt provided Maintenance free rear solid wheels Cloth look like water proof upholstery Seat Width 14" Net Weight: 19.5 kgs CP Pediatric Cerebral Palsy Description Price 17400 INR The model designed for cerebral palsy child only. Ultra light weight aluminium alloy frame Seat Width 38 cms (15") Net Weight: 18.5 kgs Epoxy powder coated frame Detachable arm rest & foot rest provided Elevated and swinging foot rest Elevated foot rest provided to elevate leg angle Height adjustable and detachable head rest Hydraulic reclining high back for a comfortable posture Hydraulic adjustable seat angle Detachable back and seat pad Extra cushion upholstery provided to under arm, head & calg Foldable Lever and paddle brakes

Heavy Duty Wheelchair specialy design for disabled and handicapped persons. They two types of Heavy Duty Wheelchair for handicapped and disability product like- Karma 8020 X Heavy Duty Wheelchair Karma 8520 Heavy Duty Wheelchair Karma 8020 X Heavy Duty Wheelchair Karma 8020 or Karma KM-8020 Heavy Duty Wheelchair specialy design for disabled and handicapped persons. Some features are mentioned below- Features It comes with detachable swing away footrests. The wheel chair has flip-back armrests. It comes with centre of gravity adjustment. The wheel chair has wide profile casters. Seat Size 20'' inch & 22'' inch Total Weight 17 K.G. Karma 8020 X Heavy Duty Wheelchair Item Code and Price Item Code: WCI-52 MRP: Rs 45162 Our Price: Rs 32900 Net Price: Rs 32242( Apply Coupon Code 'MSW2365' Get 2% Discount ) Karma 8520 Heavy Duty Wheelchair Karma 8520 or Karma KM-8520 Heavy Duty Wheelchair specialy design for disabled and handicapped persons. Some features are mentioned below- Features It comes with detachable swing away footrests. The wheel chair has flip-back armrests. It comes with centre of gravity adjustment. The wheel chair has wide profile casters. Seat Size 20'' inch & 22'' inch Total Weight 17 K.G. Karma 8520 Heavy Duty Wheelchair Item Code and Price Item Code: WCI-29 MRP: Rs 32085 Our Price: Rs 24063 Net Price: Rs 23582( Apply Coupon Code 'MSW2365' Get 2% Discount ) Heavy Duty Wheelchair Online Purchases: This Website is only a venue where Users may meet and interact with us for their sale and purchase transactions. The commercial / contractual terms include without limitation price, shipping costs, date, period, mode of delivery, warranties related to products and services including after sales services related to product(s) and services, etc., over which we have complete control and same may be the subject to change. The agreement between you and wheelchairindia.com is subject to the following terms and cond

Heavy Duty Wheelchair specialy design for disabled and handicapped persons. They two types of Heavy Duty Wheelchair for handicapped and disability product like- Karma 8020 X Heavy Duty Wheelchair Karma 8520 Heavy Duty Wheelchair Karma 8020 X Heavy Duty Wheelchair Karma 8020 or Karma KM-8020 Heavy Duty Wheelchair specialy design for disabled and handicapped persons. Some features are mentioned below- Features It comes with detachable swing away footrests. The wheel chair has flip-back armrests. It comes with centre of gravity adjustment. The wheel chair has wide profile casters. Seat Size 20'' inch & 22'' inch Total Weight 17 K.G. Karma 8020 X Heavy Duty Wheelchair Item Code and Price Item Code: WCI-52 MRP: Rs 45162 Our Price: Rs 32900 Net Price: Rs 32242( Apply Coupon Code 'MSW2365' Get 2% Discount ) Karma 8520 Heavy Duty Wheelchair Karma 8520 or Karma KM-8520 Heavy Duty Wheelchair specialy design for disabled and handicapped persons. Some features are mentioned below- Features It comes with detachable swing away footrests. The wheel chair has flip-back armrests. It comes with centre of gravity adjustment. The wheel chair has wide profile casters. Seat Size 20'' inch & 22'' inch Total Weight 17 K.G. Karma 8520 Heavy Duty Wheelchair Item Code and Price Item Code: WCI-29 MRP: Rs 32085 Our Price: Rs 24063 Net Price: Rs 23582( Apply Coupon Code 'MSW2365' Get 2% Discount ) Heavy Duty Wheelchair Online Purchases: This Website is only a venue where Users may meet and interact with us for their sale and purchase transactions. The commercial / contractual terms include without limitation price, shipping costs, date, period, mode of delivery, warranties related to products and services including after sales services related to product(s) and services, etc., over which we have complete control and same may be the subject to change. The agreement between you and wheelchairindia.com is subject to the following terms and cond

Pharmacist supervision has been the subject of debate for as long as I can remember. Strikingly, no one is sure what supervision requires. The Human Medicines Regulations 2012 say it is a criminal offence to sell or supply Pharmacy medicines or Prescription Only Medicines unless a pharmacist makes the sale or supply or, if the transaction is carried out by a non-pharmacist, that person acts under the supervision of a pharmacist. Over the years, some people have argued that supervision requires a clinical check. Others say it requires an accuracy assessment. Yet others have asserted that it requires a final check before a medicine leaves the pharmacy. Things are made more uncertain by the NHS terms of service which require prescription medicines to be supplied under the direct supervision of a pharmacist. No one knows what the word "direct" adds. The wording of the Human Medicines Regulations is not identical to the wording of earlier legislation. In particular, on the only occasions when the courts have been called upon to interpret the requirement for supervision, the Pharmacy and Poisons Act 1933 was in force. In cases decided in 1943 and 1953, the courts decided that a pharmacist who was upstairs when a supply was made could not have been supervising; and that a sale was supervised by pharmacist standing at the cash desk because the pharmacist could intervene if a sale would not be appropriate.

The parent company of Boots, Britain's largest pharmacy-led health and beauty chain, is reportedly considering putting its UK pharmacies up for sale next year for an estimated £10 billion. Walgreen Boots Alliance (WBA), the US health group that owns a stake in Boots UK since 2012, is lining up Goldman Sachs to explore a potential sale next year, as reported by Sky News. When contacted by Pharmacy Business, WBA said that it would not comment on "market speculation", noting that "Boots is an important part of the Group." The company, however, acknowledged that "it is accurate that WBA announced a renewed set of priorities and strategic direction for the Group in October, which includes a more pointed focus on North America and on healthcare."

The UK government's proposal to introduce a tobacco and vapes bill received support from the public to create the first 'smokefree generation'. The historic law to ban the sale of tobacco products to children aged 14 and younger from legally being sold cigarettes in England. King Charles delivered his first speech as monarch at the state opening of Parliament on Tuesday, 7 November. The monarch announced the introduction of the "tobacco and vapes bill" in his speech, and it read: "My Government will introduce legislation to create a smoke-free generation by restricting the sale of tobacco so that children currently aged 14 or younger can never be sold cigarettes, and restricting the sale and marketing of e-cigarettes to children."

Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83. Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade. "The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric. Biohaven forecast Nurtec sales of $825 million to $900 million in 2022. Pfizer said it expects the pills to eventually overtake the shots.

Anglo-Swedish drugmaker AstraZeneca said on Monday (January 9) that it had struck a deal to buy US-based drug developer CinCor Pharma for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease. AstraZeneca aims to combine baxdrostat with its own Farxiga, a diabetes drug whose sales ballooned after it was also shown to benefit patients with heart failure and kidney disease. Farxiga, whose sales jumped by almost 50 per cent during the first nine months of 2022 to reach $3.2 billion, belongs to a highly competitive class of drugs that includes rivals such as Boehringer Ingelheim and Eli Lilly's Jardiance. AstraZeneca gets about a third of its revenue from cancer drugs, but its heart, kidney and diabetes medicines are its second most lucrative business by sales, generating roughly $6.9 billion of the drugmaker's total revenue of more than $33 billion in the first three quarters of 2022.

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners. The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million. Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt. ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. "While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.

Specialist business property adviser, Christie & Co. has announced the sale of Manns Pharmacy, which is located in the residential area of Mapperley, Nottinghamshire. According to the broker, the community pharmacy was dispensing an average of 5,000 items per month. Gurinder Singh Mann, who owned the business for more than two decades, decided to put it on the market to allow him to retire. After undergoing a discreet sales process, the pharmacy was acquired by a pair of first-time buyer friends, named Mitan Maisuria and Rahul Patel, for an undisclosed amount.

e take pediatric disability solutions very seriously, and we're proud to offer the kinds of products that allow special needs children to develop and thrive alongside their peers. For sale below, you'll find a host of pediatric mobility devices, all designed with young people in mind. Our catalog includes: strollers, tricycles, and -- of course -- a wide variety of wheelchairs for kids. As always, we pledge to offer the best prices and all the top brands. If you're looking Wheelchairs For Children , you've come to the right place. We take pride in our expansive selection, which includes Basic Wheelchair like ,Karma Child Wheelchair, Fighter C Wheelchair, , Karma Fighter Small Wheel Wheelchair, Karma Briz 1F 24 Big Wheel Wheelchair, Karma Econ 800 Wheelchair. Wheelchair india is manufacturer, supplier, distributor and dealer of Karma Child Wheelchair for disabled and handicapped in india, Buy Karma Child Wheelchair, Karma Child Wheelchair Online Shopping, Karma Child Wheelchair Price, Karma Child Wheelchair For Sale, Karma Child Wheelchair For handicap Buy online Child Wheelchair for handicapped and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Child Wheelchair manufacturer, distributor, dealer and supplier of variety of Karma Kids Wheelchair at low price in india Still not sure what you're looking for? No Problem. Refer to our Basic wheelchair buying guides, where you'll find the information you need to make an informed decision.